ARVINAS, INC.

ARVNSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1655759

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	—	$46.7M
Research and Development Expense	$379.7M	$315.0M	$180.4M	$108.4M	$67.2M
Operating Expenses	$480.0M	$394.6M	$242.0M	$146.7M	$94.5M
Operating Income (Loss)	-$401.5M	-$263.2M	-$188.4M	-$120.8M	-$51.5M
Interest Expense	—	$0.00	$0.00	—	$100.0K
Nonoperating Income (Expense)	$37.6M	$12.2M	$4.3M	$5.6M	$5.9M
Income Tax Expense (Benefit)	$900.0K	$20.9M	$0.00	$0.00

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$1.1B	$1.3B	$1.3B	$1.6B	$717.4M
Assets, Current	$1.1B	$1.3B	$1.2B	$1.6B	$703.1M
Cash and Cash Equivalents, at Carrying Value	$311.7M	$81.3M	$108.3M	$588.4M	$588.4M
Accounts Receivable, after Allowance for Credit Loss, Current	$0.00	$1.0M	$15.0M	$1.0M	$1.0M
Liabilities	$529.7M	$644.6M	$703.9M	$799.9M	$75.2M
Liabilities, Current	$229.8M	$257.1M	$295.1M	$261.7M	$49.2M
Long-term Debt	$800.0K	$1.0M	$1.0M	$1.0M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$347.8M	-$273.5M	$559.4M	-$89.7M	-$40.6M
Net Cash Provided by (Used in) Investing Activities	$203.5M	$242.8M	-$1.3B	$164.3M	-$93.1M
Net Cash Provided by (Used in) Financing Activities	$374.7M	$4.7M	$278.6M	$504.6M	$139.7M
Payments to Acquire Property, Plant, and Equipment	$2.9M	$6.8M	$4.7M	$6.4M	$6.3M
Payments for Repurchase of Common Stock	$0.00	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)